Skip to main content

Advertisement

Table 1 Patients’ table

From: Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT

Serum donor Age (years) Sex Birch pollen ImmunoCAP Other sensitizations
Allergy symptoms Skin prick test Rhino-conjunctivitis total symptom scores Bet v 1-specific IgE (kU/l) Skin prick test
T0 T1 T2 T0 T1 T2
P1 41 m RC +++ 6 2 1 40.2 42.7 19.8 Mites, hazel pollen
P2 50 m RC +++ 8 1 1 4.4 5.8 4.8 Grass, hazel pollen
P3 54 m RC + 3 0 2 26.3 53.3 38.0 Mites, hazel pollen
P4 45 m RC ++ 3 2 0 51.1 159.0 81.3 Mold, hazel pollen
P5 63 f RC + 4 3 1 10.3 17.5 10.0 Mugwort, ragweed, hazel pollen
NA 47 f None Neg     < 0.01    None
NBA 26 f None Neg     < 0.01    Mites
  1. P1–5, AIT patients; NA, non-allergic serum donor; NBA, non-birch allergic serum donor; RC, rhino-conjunctivitis; +, mild reaction; ++, moderate reaction; +++, strong reaction; Neg, negative; T0, before AIT; T1, 2 weeks after reaching the maintenance dose; T2, 1 year after starting AIT